Pembrolizumab (monotherapy)
Treatment for Uterine Cancer
Typical Dosage: 200mg IV every 3 weeks or 400mg IV every 6 weeks
Effectiveness
60%
Safety Score
40%
Clinical Trials
36
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
200mg IV every 3 weeks or 400mg IV every 6 weeks
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$104,000/QALY
QALYs Gained
1.14
Outcome-Based Costs
Cost per Responder
$412,500
Cost per Remission
$1,650,000
Comparison vs Chemotherapy (Doxorubicin or Paclitaxel)
Cost Difference
+$65,000/year
More expensive
QALY Difference
+1.14 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (monotherapy) Outcomes
for Uterine Cancer
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+40%
Remission Rate
+10%
Common Side Effects
Fatigue
+40%
Musculoskeletal pain
+25%
Diarrhea
+25%
Rash
+20%
Immune-related adverse events (colitis, hepatitis, pneumonitis, endocrinopathies)
+15%
Sources:
Active Clinical Trials
13 active trials recruiting for Pembrolizumab (monotherapy) in Uterine Cancer
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619NOT YET RECRUITINGPHASE1, PHASE2
160 participants
INTERVENTIONAL
Morristown, United States +7 more
Started: Dec 1, 2025
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT05311618ACTIVE NOT RECRUITINGPHASE1
71 participants
INTERVENTIONAL
Denver, United States +5 more
Started: May 11, 2022
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430RECRUITINGPHASE1, PHASE2
365 participants
INTERVENTIONAL
Los Angeles, United States +12 more
Started: Mar 23, 2023
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Little Rock, United States +2 more
Started: Mar 21, 2025
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574ACTIVE NOT RECRUITINGPHASE1
130 participants
INTERVENTIONAL
Gilbert, United States +8 more
Started: Mar 31, 2022
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337ACTIVE NOT RECRUITINGPHASE1, PHASE2
179 participants
INTERVENTIONAL
Los Angeles, United States +26 more
Started: Jun 9, 2021
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706RECRUITINGPHASE1
77 participants
INTERVENTIONAL
New Haven, United States +4 more
Started: Aug 30, 2023
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692RECRUITINGPHASE1, PHASE2
115 participants
INTERVENTIONAL
San Diego, United States +26 more
Started: Aug 27, 2021
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168RECRUITINGPHASE1
200 participants
INTERVENTIONAL
Denver, United States +5 more
Started: Nov 7, 2025
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981RECRUITINGPHASE1
130 participants
INTERVENTIONAL
Detroit, United States +6 more
Started: Apr 3, 2023
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT03786081ACTIVE NOT RECRUITINGPHASE1, PHASE2
214 participants
INTERVENTIONAL
Phoenix, United States +70 more
Started: Feb 27, 2019
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT06400472RECRUITINGPHASE1
495 participants
INTERVENTIONAL
Scottsdale, United States +22 more
Started: May 20, 2024
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
NCT06502743RECRUITINGPHASE2
92 participants
INTERVENTIONAL
Kyeonggi-do, South Korea +5 more
Started: Sep 12, 2024
Completed Clinical Trials
4 completed trials for Pembrolizumab (monotherapy) in Uterine Cancer
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
NCT06894771COMPLETEDPHASE1
5 participants
INTERVENTIONAL
Hackensack, United States +6 more
Started: Apr 23, 2025
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
NCT02635672COMPLETEDPHASE1
110 participants
INTERVENTIONAL
Springdale, United States +15 more
Started: Feb 10, 2016
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
NCT03674567COMPLETEDPHASE1, PHASE2
323 participants
INTERVENTIONAL
Gilbert, United States +34 more
Started: Sep 25, 2018
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03849469COMPLETEDPHASE1
78 participants
INTERVENTIONAL
Encinitas, United States +27 more
Started: May 29, 2019
Showing 20 of 39 total trials